Scholar Rock Holding Corporation
SRRK$2.60B
Mid CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaCAMBRIDGE128 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 5, 2026
6wMarket Overview
Stock performance and key metrics
SRRK News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
Apitegromab
Spinal Muscular Atrophy
Tirzepatide
Overweight and Obesity
SRK-015
Spinal Muscular Atrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Apitegromab | Phase 3 | Spinal Muscular Atrophy | - | - |
Tirzepatide | Phase 2 | Overweight and Obesity | - | - |
SRK-015 | Phase 2 | Spinal Muscular Atrophy | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply